Free Trial 中
Wind ESG Rating

Access to ESG rating for China A-Shares and Hong Kong listed companies.

智飞生物

300122.SZ
Wind Industry: 医疗保健 > 医药生物 > 生物科技Ⅲ > 生物科技Ⅳ

公司成立于2002年，是一家集疫苗、生物制品研发、生产、销售、配送及进出口为一体的国际化、全产业链高科技生物制药企业。公司始终秉持“社会效益第一，企业效益第二”的经营宗旨，担当“防未病治已病，守护人类健康”的使命，贯彻“技术＆市场”双轮驱动的发展模式，以民众健康需求为导向，不断完善“预防＆治疗”的产业布局，强化科技创新与商业化落地能力。

ESG Score Industry Ranking:
7 / 165 (生物科技Ⅲ)

ESG Rating Distribution(生物科技Ⅲ)

Trend of Rating

2022-05-05: A; 2023-03-23: AA; 2024-05-15: A; 2025-06-25: AA; 2026-07-01: AA A2022.05 AA2023.03 A2024.05 AA2025.06 AA2026.07

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.16Updated on 2026-10-29
08.1610
Management & Practices Score：5.19Updated on 2026-08-30
05.197
Controversies Score：2.97Updated on 2026-10-29
02.973

ESG Score Comparison

Environmental Social Governance 智飞生物生物科技Ⅲ Average
IndicatorCompany ScoreIndustry AverageWeight
Environmental5.403.6712.53%
Social7.424.5457.57%
Governance8.245.7829.91%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

  • 500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
  • 1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB
More Details

Peer Comparison(165 companies in the industry) ?

RankingCodeSecurity NameESG RatingESG ScoreControversies ScoreManagement & Practices ScoreEnvironmentalSocialGovernance
1603392.SH万泰生物AA8.862.965.907.578.548.58
2002252.SZ上海莱士AA8.682.995.697.758.128.29
31801.HK信达生物AA8.623.005.627.788.038.12
4300142.SZ沃森生物AA8.422.945.485.488.148.21
52269.HK药明生物AA8.283.005.288.457.477.29
61530.HK三生制药AA8.262.995.267.567.437.68
7920344.BJ三元基因AA8.162.965.204.337.977.69
7300122.SZ智飞生物AA8.162.975.195.407.428.24
96660.HK艾美疫苗AA8.123.005.126.397.377.57
106855.HK亚盛医药AA8.112.995.127.217.736.59